Amgen Lung Cancer Drug Fails Goals For Improving Survival
Posted Mar 30 2011 4:09pm
These are tough drugs to create and sad that this one did not make the grade. What is also a bit disappointing too was that this was a joint effort with Japanese Takeda Drug so not good news for them either in light of everything else Japan is dealing with. In other cancer news of late, Amgen made a purchase of another cancer biotech company that is doing research for treating melanoma and a few other types of cancer and are also moving into a new building in Freemont, CA. BD
An experimental treatment for lung cancer made by Amgen Inc. and Takeda Pharmaceutical Co. failed to help patients live longer in a late-stage study needed for regulatory approval. The drug, called motesanib, didn't meet its main goal of improving survival in a study of 1,090 patients with non- squamous non-small cell lung cancer, the companies said in a statement today. Detailed results from the study will be presented at a medical meeting, the companies said.